January 17, 2015
On Jan. 9, the U.S. Food and Drug Administration (FDA) approved a three-in-one test that detects HIV, hepatitis C and hepatitis B.
The test, manufactured by Roche, is the second version of the "cobas TaqScreen MPX Test." This updated version provides increased sensitivity and is the only test approved by the FDA to detect the three aforementioned viruses together.
The real-time, multi-dye PCR assay will be used to test "donations of human whole blood and blood components including source plasma," according to Roche's press release.
"The combination of viral target detection and identification steps on a fully automated system offers workflow advantages to blood and plasma testing centers by eliminating the need for consecutive rounds of testing, and facilitating earlier donor counseling in the event of a positive result," the manufacturer stated.
Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|